Please use this identifier to cite or link to this item:
Title: Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.
Austin Authors: Howden, Benjamin P ;Ward, Peter B;Charles, Patrick G P ;Korman, Tony M;Fuller, Andrew;du Cros, Philipp;Grabsch, Elizabeth A ;Roberts, Sally A;Robson, Jenny;Read, Kerry;Bak, Narin;Hurley, James;Johnson, Paul D R ;Morris, Arthur J;Mayall, Barrie C;Grayson, M Lindsay 
Affiliation: Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 29-Jan-2004
Publication information: Clinical Infectious Diseases 2004; 38(4): 521-8
Abstract: Although infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility (SA-RVS) have been reported from a number of countries, including Australia, the optimal therapy is unknown. We reviewed the clinical features, therapy, and outcome of 25 patients with serious infections due to SA-RVS in Australia and New Zealand. Eight patients had endocarditis, 9 had bacteremia associated with deep-seated infection, 6 had osteomyelitis or septic arthritis, and 2 had empyema. All patients had received vancomycin before the isolation of SA-RVS, and glycopeptide treatment had failed for 19 patients (76%). Twenty-one patients subsequently received active treatment, which was effective for 16 patients (76%). Eighteen patients received linezolid, which was effective in 14 (78%), including 4 patients with endocarditis. Twelve patients received a combination of rifampicin and fusidic acid. Surgical intervention was required for 15 patients (60%). Antibiotic therapy, especially linezolid with or without rifampicin and fusidic acid, in conjunction with surgical debulking is effective therapy for the majority of patients with serious infections (including endocarditis) caused by SA-RVS.
Gov't Doc #: 14765345
DOI: 10.1086/381202
Journal: Clinical Infectious Diseases
Type: Journal Article
Subjects: Acetamides.therapeutic use
Aged, 80 and over
Anti-Infective Agents.therapeutic use
Methicillin Resistance
Microbial Sensitivity Tests
Middle Aged
Oxazolidinones.therapeutic use
Rifampin.therapeutic use
Staphylococcal Infections.drug therapy
Staphylococcus aureus.drug effects
Treatment Outcome
Vancomycin Resistance
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.